126 related articles for article (PubMed ID: 9787326)
1. An infant with neuroblastoma and MYCN amplification found through mass screening.
Taga T; Okamoto N; Hisano T; Tanaka T; Shimada M; Okabe H; Shimada H; Ohta S
J Pediatr Hematol Oncol; 1998; 20(5):486-8. PubMed ID: 9787326
[TBL] [Abstract][Full Text] [Related]
2. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
Chan EL; Harris RE; Emery KH; Gelfand MJ; Collins MH; Gruppo RA
Pediatr Blood Cancer; 2007 Apr; 48(4):479-82. PubMed ID: 16333837
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
4. Hemorrhagic shock due to spontaneous rupture of adrenal neuroblastoma in an infant: a rare case and review of the literature.
Honda S; Miyagi H; Minato M; Kubota KC; Okada T
J Pediatr Hematol Oncol; 2012 Nov; 34(8):635-7. PubMed ID: 23018564
[TBL] [Abstract][Full Text] [Related]
5. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
6. Bilateral adrenal neuroblastoma is different.
Pederiva F; Andres A; Sastre A; Alves J; Martinez L; Tovar JA
Eur J Pediatr Surg; 2007 Dec; 17(6):393-6. PubMed ID: 18072022
[TBL] [Abstract][Full Text] [Related]
7. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
8. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
9. Infantile Stage M Neuroblastoma With 11q Deletion, Mimicking Stage MS.
Yoshimoto Suzuki Y; Yamanaka J; Miyazaki O; Nozawa K; Ohira M; Kamijo T; Shichino H
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e779-e781. PubMed ID: 35001057
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
11. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
12. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
13. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
14. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
15. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
16. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
[TBL] [Abstract][Full Text] [Related]
17. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
18. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
19. Features and outcome of neuroblastoma detected before birth.
Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
[TBL] [Abstract][Full Text] [Related]
20. Locoregional MYCN-amplified neuroblastoma.
Morales La Madrid A; Volchenboum S; Gastier-Foster JM; Pyatt R; Liu D; Pytel P; Lavarino C; Rodriguez E; Cohn SL
Pediatr Blood Cancer; 2012 Oct; 59(4):736-8. PubMed ID: 22213566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
